Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: Future directions

Journal of Alzheimer's Disease

Volumn 15, Issue 2, 2008, Pages 327-338

  Carlsson, Cynthia M ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Biological markers; Clinical trials; Cognition; Neuropsychological tests

Indexed keywords

AMYLOID BETA PROTEIN; DONEPEZIL; HOMOTAURINE;

ALZHEIMER DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL; HUMAN; METHODOLOGY; NEUROBIOLOGY; NEUROPSYCHOLOGICAL TEST; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW;

EID: 54249114011     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2008-15214     Document Type: Review

References (92)

1. Alzheimer's Disease Cooperative Study, A Randomized Double-Blind Placebo-Controlled Trial of the Effects of Docosahexaenoic Acid (DHA) in Slowing the Progression of Alzheimer's Disease, https://adcs.ucsd.edu/DHA_protocol.htm. Last updated January 26, 2007, Accessed April 9, 2008.
2. Alzheimer Research Forum, FDA Deems US Alzhemed Trial Results Inconclusive, http://www.alzforum.org/new/detail.asp?id=1647. Accessed April 9, 2008.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet 360 (2002), 7-22.
4. P.S. Aisen, K.L. Davis, J.D. Berg, K. Schafer, K. Campbell, R.G. Thomas, M.F. Weiner, M.R. Farlow, M. Sano, M. Grundman and L.J. Thal, A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study, Neurology 54 (2000), 588-593.
5. P.S. Aisen, J. Schmeidler and G.M. Pasinetti, Randomized pilot study of nimesulide treatment in Alzheimer's disease, Neurology 58 (2002), 1050-1054.
6. P.S. Aisen, S. Egelko, H. Andrews, R. Diaz-Arrastia, M. Weiner, C. DeCarli, W. Jagust, J.W. Miller, R. Green, K. Bell and M. Sano, A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease, Am J Geriatr Psychiatry 11 (2003), 246-249.
7. P.S. Aisen, K.A. Schafer, M. Grundman, E. Pfeiffer, M. Sano, K.L. Davis, M.R. Farlow, S. Jin, R.G. Thomas and L.J. Thal, Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial, JAMA 289 (2003), 2819-2826.
8. P.S. Aisen, S. Gauthier, B. Vellas, R. Briand, D. Saumier, J. Laurin and D. Garceau, Alzhemed: a potential treatment for Alzheimer's disease, Curr Alzheimer Res 4 (2007), 473-478.
9. P.S. Aisen, S. Jin, R.G. Thomas, M. Sano, R. Diaz-Arrastia and L. Thal, ADCS Homocysteine Trial, Alzheimers Dement 3(Suppl 2) (2007), S199.
10. P. Bailey, Biological markers in Alzheimer's disease, Can J Neurol Sci 34(Suppl 1) (2007), S72-76.
11. P. Bentham, R. Gray, E. Sellwood, R. Hills, P. Crome and J. Raftery, Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial, Lancet Neurol 7 (2008), 41-49.
12. R. Brookmeyer, E. Johnson, K. Ziegler-Graham and H.M. Arrighi, Forecasting the global burden of Alzheimer's disease, Alzheimers Dement 3 (2007), 186-191.
13. C.M. Carlsson, Homocysteine lowering with folic acid and vitamin B supplements: effects on cardiovascular disease in older adults, Drugs Aging 23 (2006), 491-502.
14. C.M. Carlsson, C.E. Gleason, T.M. Hess, K.A. Moreland, H.M. Blazel, R.L. Koscik, N.T. Schreiber, S.C. Johnson, C.S. Atwood, L. Puglielli, B.P. Hermann, P.E. McBride, J.H. Stein, M.A. Sager and S. Asthana, Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease, J Alzheimers Dis 13 (2008), 187-197.
15. A.S. Chappell, C. Gonzales, J. Williams, M.M. Witte, R.C. Mohs and R. Sperling, AMPA potentiator treatment of cognitive deficits in Alzheimer disease, Neurology 68 (2007), 1008-1012.
16. H. Chertkow and S. Black, Imaging biomarkers and their role in dementia clinical trials, Can J Neurol Sci 34(Suppl 1) (2007), S77-83.
17. C. Courtney, D. Farrell, R. Gray, R. Hills, L. Lynch, E. Sellwood, S. Edwards, W. Hardyman, J. Raftery, P. Crome, C. Lendon, H. Shaw and P. Bentham, Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial, Lancet 363 (2004), 2105-2115.
18. J.L. Cummings, R. Doody and C. Clark, Disease-modifying therapies for Alzheimer disease: challenges to early intervention, Neurology 69 (2007), 1622-1634.
19. V.G. De Gruttola, P. Clax, D.L. DeMets, G.J. Downing, S.S. Ellenberg, L. Friedman, M.H. Gail, R. Prentice, J. Wittes and S.L. Zeger, Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop, Control Clin Trials 22 (2001), 485-502.
20. C.A. de Jager, M.M. Budge and R. Clarke, Utility of TICS-M for the assessment of cognitive function in older adults, Int J Geriatr Psychiatry 18 (2003), 318-324.
21. R. Doody, We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development, Alzheimers Dement 4(Suppl 1) (2008), S21-S25.
22. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, J. Cummings, A. Delacourte, D. Galasko, S. Gauthier, G. Jicha, K. Meguro, J. O'Brien, F. Pasquier, P. Robert, M. Rossor, S. Salloway, Y. Stern, P.J. Visser and P. Scheltens, Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria, Lancet Neurol 6 (2007), 734-746.
23. H. Fillit, Drug discovery and the prevention of Alzheimer's disease, Alzheimers Dement 4(Suppl 1) (2008), S26-S28.
24. A.S. Fleisher, B.B. Sowell, C. Taylor, A.C. Gamst, R.C. Petersen and L.J. Thal, Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment, Neurology 68 (2007), 1588-1595.
25. T.R. Fleming and D.L. DeMets, Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125 (1996), 605-613.
26. Y. Freund-Levi, M. Eriksdotter-Jonhagen, T. Cederholm, H. Basun, G. Faxen-Irving, A. Garlind, I. Vedin, B. Vessby, L.O. Wahlund and J. Palmblad, Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial, Arch Neurol 63 (2006), 1402-1408.
27. S. Gauthier, Outcomes for assessment of symptomatic and stabilization/disease modifying drugs, Can J Neurol Sci 34(Suppl 1) (2007), S23-26.
28. S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Griffith, N.C. Fox, L. Eisner, L. Kirby, M.B. Rovira, F. Forette and J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial, Neurology 64 (2005), 1553-1562.
29. R.C. Green, L.A. Cupples, R. Go, K.S. Benke, T. Edeki, P.A. Griffith, M. Williams, Y. Hipps, N. Graff-Radford, D. Bachman and L.A. Farrer, Risk of dementia among white and African American relatives of patients with Alzheimer disease, JAMA 287 (2002), 329-336.
30. R.C. Green and S.T. DeKosky, Primary prevention trials in Alzheimer disease, Neurology 67 (2006), S2-5.
31. A.R. Group, C.G. Lyketsos, J.C. Breitner, R.C. Green, B.K. Martin, C. Meinert, S. Piantadosi and M. Sabbagh, Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial, Neurology 68 (2007), 1800-1808.
32. M. Grundman, R.C. Petersen, S.H. Ferris, R.G. Thomas, P.S. Aisen, D.A. Bennett, N.L. Foster, C.R. Jack, Jr., D.R. Galasko, R. Doody, J. Kaye, M. Sano, R. Mohs, S. Gauthier, H.T. Kim, S. Jin, A.N. Schultz, K. Schafer, R. Mulnard, C.H. van Dyck, J. Mintzer, E.Y. Zamrini, D. Cahn-Weiner and L.J. Thal, Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials, Arch Neurol 61(2004), 59-66.
33. S.M. Harman, E.A. Brinton, M. Cedars, R. Lobo, J.E. Manson, G.R. Merriam, V.M. Miller, F. Naftolin and N. Santoro, KEEPS: The Kronos Early Estrogen Prevention Study, Climacteric 8 (2005), 3-12.
34. J. Harrison, S.L. Minassian, L. Jenkins, R.S. Black, M. Koller and M. Grundman, A neuropsychological test battery for use in Alzheimer disease clinical trials, Arch Neurol 64 (2007), 1323-1329.
35. R.J. Hodes, N. Buckholtz, V. Cahan and M. Morrison-Bogorad, Eyes on the prize: Federal Alzheimer's research effort aims to facilitate interventions, Alzheimers Dement 4(Suppl 1) (2008), S37-S47.
36. D.B. Hogan, Improving drug trials for mild to moderate Alzheimer's disease, Can J Neurol Sci 34(Suppl 1) (2007), S97-102.
37. C.R. Jack, Jr., R.C. Petersen, M. Grundman, S. Jin, A. Gamst, C.P. Ward, D. Sencakova, R.S. Doody and L.J. Thal, Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI, Neurobiol Aging (2008), in press.
38. S. Jayadev, E.J. Steinbart, Y.Y. Chi, W.A. Kukull, G.D. Schellenberg and T.D. Bird, Conjugal Alzheimer disease: risk in children when both parents have Alzheimer disease, Arch Neurol 65 (2008), 373-378.
39. S.C. Johnson, T.W. Schmitz, M.A. Trivedi, M.L. Ries, B.M. Torgerson, C.M. Carlsson, S. Asthana, B.P. Hermann and M.A. Sager, The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation, J Neurosci 26 (2006), 6069-6076.
40. R.W. Jones, M. Kivipelto, H. Feldman, D.L. Sparks, R. Doody, D.D. Waters, J. Hey-Hadavi, A. Breazna, R.J. Schindler and H. Ramos, The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics, Alzheimers Dement 4 (2008), 145-153.
41. E. Kaplan, H. Goodglass and S. Weintraub, The Boston Naming Test. 2nd edition, Lea and Febiger, Philadelphia, PA, 1983.
42. J.H. Karlawish, Donepezil delay to nursing home placement study is flawed, J Am Geriatr Soc 52 (2004), 845; author reply 845-846.
43. J. Kaye, Home-based technologies: A new paradigm for conducting dementia prevention trials, Alzheimers Dement 4(Suppl 1) (2008), S60-S66.
44. A. Kirk, Target symptoms and outcome measures: cognition, Can J Neurol Sci 34(Suppl 1) (2007), S42-46.
45. A. Kluger, S.H. Ferris, J. Golomb, M.S. Mittelman and B. Reisberg, Neuropsychological prediction of decline to dementia in nondemented elderly, J Geriatr Psychiatry Neurol 12(1999), 168-179.
46. A. Kurz, M. Farlow, P. Quarg and R. Spiegel, Disease stage in Alzheimer disease and treatment effects of rivastigmine, Alzheimer Dis Assoc Disord 18 (2004), 123-128.
47. P. Leber, ed., Guidelines for the Clinical Evaluation of Antidementia Drugs. First Draft. Rockville, MD, Division of Neuropharmacological Drug Products, Food and Drug Administration, 1990.
48. P.H. Lu, D.A. Masterman, R. Mulnard, C. Cotman, B. Miller, K. Yaffe, E. Reback, V. Porter, R. Swerdloff and J.L. Cummings, Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men, Arch Neurol 63 (2006), 177-185.
49. J.L. Mack and P.J. Whitehouse, Quality of Life in Dementia: state of the art-report of the International Working Group for Harmonization of Dementia Drug Guidelines and the Alzheimer's Society satellite meeting, Alzheimer Dis Assoc Disord 15 (2001), 69-71.
50. C. MacKnight, Study design in dementia drug trials, Can J Neurol Sci 34(Suppl 1) (2007), S19-22.
51. R.B. Mani, The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint, Stat Med 23(2004), 305-314.
52. F. Massoud, The role of functional assessment as an outcome measure in antidementia treatment, Can J Neurol Sci 34(Suppl 1) (2007), S47-51.
53. I.G. McKeith, D. Galasko, K. Kosaka, E.K. Perry, D.W. Dickson, L.A. Hansen, D.P. Salmon, J. Lowe, S.S. Mirra, E.J. Byrne, G. Lennox, N.P. Quinn, J.A. Edwardson, P.G. Ince, C. Bergeron, A. Burns, B.L. Miller, S. Lovestone, D. Collerton, E.N. Jansen, C. Ballard, R.A. de Vos, G.K. Wilcock, K.A. Jellinger and R.H. Perry, Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop, Neurology 47 (1996), 1113-1124.
54. R. Miller, W. Ewy, B.W. Corrigan, D. Ouellet, D. Hermann, K.G. Kowalski, P. Lockwood, J.R. Koup, S. Donevan, A. El-Kattan, C.S. Li, J.L. Werth, D.E. Feltner and R.L. Lalonde, How modeling and simulation have enhanced decision making in new drug development, J Pharmacokinet Pharmacodyn 32 (2005), 185-197.
55. R.C. Mohs, W.G. Rosen and K.L. Davis, The Alzheimer's disease assessment scale: an instrument for assessing treatment efficacy, Psychopharmacol Bull 19 (1983), 448-450.
56. R.C. Mohs, D. Knopman, R.C. Petersen, S.H. Ferris, C. Ernesto, M. Grundman, M. Sano, L. Bieliauskas, D. Geldmacher, C. Clark and L.J. Thal, Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study, Alzheimer Dis Assoc Disord 11(Suppl 2) (1997), S13-21.
57. A.U. Monsch, M.W. Bondi, N. Butters, D.P. Salmon, R. Katzman and L.J. Thal, Comparisons of verbal fluency tasks in the detection of dementia of the Alzheimer type, Arch Neurol 49(1992), 1253-1258.
58. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C. Jack, W. Jagust, J.Q. Trojanowski, A.W. Toga and L. Beckett, The Alzheimer's disease neuroimaging initiative, Neuroimaging Clin N Am 15 (2005), 869-877, xi-xii.
59. R.A. Mulnard, C.W. Cotman, C. Kawas, C.H. van Dyck, M. Sano, R. Doody, E. Koss, E. Pfeiffer, S. Jin, A. Gamst, M. Grundman, R. Thomas and L.J. Thal, Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study, JAMA 283 (2000), 1007-1015.
60. J.C. Mundt, L.M. Kinoshita, S. Hsu, J.A. Yesavage and J.H. Greist, Telephonic Remote Evaluation of Neuropsychological Deficits (TREND): longitudinal monitoring of elderly community-dwelling volunteers using touch-tone telephones, Alzheimer Dis Assoc Disord 21 (2007), 218-224.
61. G. Naglie, Quality of life in dementia, Can J Neurol Sci 34(Suppl 1) (2007), S57-61.
62. N.L. Pedersen, M. Gatz, S. Berg and B. Johansson, How heritable is Alzheimer's disease late in life? Findings from Swedish twins, Ann Neurol 55 (2004), 180-185.
63. R.C. Petersen, R.G. Thomas, M. Grundman, D. Bennett, R. Doody, S. Ferris, D. Galasko, S. Jin, J. Kaye, A. Levey, E. Pfeiffer, M. Sano, C.H. van Dyck and L.J. Thal, Vitamin E and donepezil for the treatment of mild cognitive impairment, N Engl J Med 352 (2005), 2379-2388.
64. S.R. Rapp, M.A. Espeland, S.A. Shumaker, V.W. Henderson, R.L. Brunner, J.E. Manson, M.L. Gass, M.L. Stefanick, D.S. Lane, J. Hays, K.C. Johnson, L.H. Coker, M. Dailey and D. Bowen, Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA 289 (2003), 2663-2672.
65. R.E. Ready and B.R. Ott, Quality of Life measures for dementia, Health Qual Life Outcomes 1 (2003), 11.
66. M.A. Reger, G.S. Watson, P.S. Green, C.W. Wilkinson, L.D. Baker, B. Cholerton, M.A. Fishel, S.R. Plymate, J.C. Breitner, W. DeGroodt, P. Mehta and S. Craft, Intranasal insulin improves cognition and modulates beta-amyloid in early AD, Neurology 70 (2008), 440-448.
67. S.A. Reines, G.A. Block, J.C. Morris, G. Liu, M.L. Nessly, C.R. Lines, B.A. Norman and C.C. Baranak, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology 62 (2004), 66-71.
68. B. Reisberg, L. Schneider, R. Doody, R. Anand, H. Feldman, H. Haraguchi, R. Kumar, U. Lucca, C.A. Mangone, E. Mohr, J.C. Morris, S. Rogers and T. Sawada, Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines, Alzheimer Dis Assoc Disord 11(Suppl 3) (1997), 8-18.
69. E.D. Roberson and L. Mucke, 100 years and counting: prospects for defeating Alzheimer's disease, Science 314(2006), 781-784.
70. K. Rockwood, S.E. Black, A. Robillard and I. Lussier, Potential treatment effects of donepezil not detected in Alzheimer's disease clinical trials: a physician survey, Int J Geriatr Psychiatry 19 (2004), 954-960.
71. K. Rockwood, Global assessment measures for assessing efficacy in dementia drug trials, Can J Neurol Sci 34(Suppl 1) (2007), S52-56.
72. K. Rockwood, S. Fay, M. Gorman, D. Carver and J.E. Graham, The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial, BMC Neurol 7 (2007), 26.
73. M.A. Sager, B. Hermann and A. La Rue, Middle-aged children of persons with Alzheimer's disease: APOE genotypes and cognitive function in the Wisconsin Registry for Alzheimer's Prevention, J Geriatr Psychiatry Neurol 18 (2005), 245-249.
74. P. Santaguida, McMaster University. Evidence-based Practice Center, et al., Pharmacological treatment of dementia. Evidence report/technology assessment no. 97, 2004. [Rockville, Md., Agency for Healthcare Research and Quality].
75. L.S. Schneider, AD2000: donepezil in Alzheimer's disease, Lancet 363 (2004), 2100-2101.
76. N. Schoenmaker and W.A. Van Gool, The age gap between patients in clinical studies and in the general population: a pitfall for dementia research, Lancet Neurol 3 (2004), 627-630.
77. B. Seltzer, P. Zolnouni, M. Nunez, R. Goldman, D. Kumar, J. Ieni and S. Richardson, Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial, Arch Neurol 61 (2004), 1852-1856.
78. S.A. Shumaker, C. Legault, S.R. Rapp, L. Thal, R.B. Wallace, J.K. Ockene, S.L. Hendrix, B.N. Jones, 3rd, A.R. Assaf, R.D. Jackson, J.M. Kotchen, S. Wassertheil-Smoller and J. Wactawski-Wende, Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial, JAMA 289 (2003), 2651-2662.
79. G.D. Silverberg, M. Mayo, T. Saul, J. Fellmann, J. Carvalho and D. McGuire, Continuous CSF drainage in AD. Results of a double-blind, randomized, placebo-controlled study, Neurology (2008),
80. M. Simons, F. Schwarzler, D. Lutjohann, K. von Bergmann, K. Beyreuther, J. Dichgans, H. Wormstall, T. Hartmann and J.B. Schulz, Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blind trial, Ann Neurol 52 (2002), 346-350.
81. A. Smith, Symbol digit modalities test, Western Psychological Services, Los Angeles, 1973.
82. D.L. Sparks, M.N. Sabbagh, D.J. Connor, J. Lopez, L.J. Launer, P. Browne, D. Wasser, S. Johnson-Traver, J. Lochhead and C. Ziolwolski, Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results, Arch Neurol 62 (2005), 753-757.
83. D.L. Streiner, Alternatives to placebo-controlled trials, Can J Neurol Sci 34(Suppl 1) (2007), S37-41.
84. L.J. Thal, M. Grundman, J. Berg, K. Ernstrom, R. Margolin, E. Pfeiffer, M.F. Weiner, E. Zamrini and R.G. Thomas, Idebenone treatment fails to slow cognitive decline in Alzheimer's disease, Neurology 61 (2003), 1498-1502.
85. L.J. Thal, K. Kantarci, E.M. Reiman, W.E. Klunk, M.W. Weiner, H. Zetterberg, D. Galasko, D. Pratico, S. Griffin, D. Schenk and E. Siemers, The role of biomarkers in clinical trials for Alzheimer disease, Alzheimer Dis Assoc Disord 20 (2006), 6-15.
86. J.R. Tinklenberg, H.C. Kraemer, K. Yaffe, L. Ross, J. Sheikh, J.W. Ashford, J.A. Yesavage and J.L. Taylor, Donepezil treatment and Alzheimer disease: can the results of randomized clinical trials be applied to Alzheimer disease patients in clinical practice? Am J Geriatr Psychiatry 15 (2007), 953-960.
87. B. Vellas, S. Andrieu, C. Sampaio and G. Wilcock, Disease-modifying trials in Alzheimer's disease: a European task force consensus, Lancet Neurol 6 (2007), 56-62.
88. B. Vellas, S. Andrieu, C. Sampaio, N. Coley and G. Wilcock, Endpoints for trials in Alzheimer's disease: a European task force consensus, Lancet Neurol 7 (2008), 436-450.
89. D. Wechsler, WAIS-R Wechsler adult intelligence scale-III, Psychological Corporation, New York, N.Y., 1991.
90. D. Wechsler, Wechsler Memory Scales-3rd Edition, The Psychological Corporation, San Antonio, TX, 1997.
91. J.D. Williamson, M.E. Miller, R.N. Bryan, R.M. Lazar, L.H. Coker, J. Johnson, T. Cukierman, K.R. Horowitz, A. Murray and L.J. Launer, The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods, Am J Cardiol 99 (2007), 112i-122i.
92. O.M. Wolkowitz, J.H. Kramer, V.I. Reus, M.M. Costa, K. Yaffe, P. Walton, M. Raskind, E. Peskind, P. Newhouse, D. Sack, E. De Souza, C. Sadowsky and E. Roberts, DHEA treatment of Alzheimer's disease: a randomized, double-blind, placebo-controlled study, Neurology 60 (2003), 1071-1076.